Literature DB >> 21160994

Construction of non-covalent single-chain Fv dimers for hepatocellular carcinoma and their biological functions.

Cai-Qun Bie1, Dong-Hua Yang, Xu-Jing Liang, Shao-Hui Tang.   

Abstract

AIM: To create new diabodies with improved binding activity to antigen of the variable light - variable heavy (VH-VL) oriented single-chain Fv dimers genes (scFv).
METHODS: The linker between VH and VL genes was shortened to 3-5 amino acid residues and cloned into the vector pCANTAB5E. The recombinant plasmids were transformed into TG1 cells and sequenced. The positive transformed cells were infected by M13K07 helper phage to form human recombinant phage antibodies. Expressed products were identified by SDS-PAGE, Western blotting, size exclusion gel chromatography (SEC), ELISA and immunohistochemistry.
RESULTS: Three scFv (scFv-3, scFv-4, scFv-5) were constructed successfully with binding ability to hepatocellular carcinoma 3.5-6 fold greater than their parental scFv. The single-chain Fv dimer (scFv-5, termed BDM3) with the best binding ability was successfully expressed in Yeast pichlia, as shown by. SDS-PAGE and Western blotting. SEC results suggested the molecular weight of the expressed products was about 61 kDa. Expressed products showed significantly stronger binding to hepatocellular carcinoma cells than scFv, still having 50% binding activity even after 16 h incubation as 37°C. The purified dimers were bound specifically to the tumor antigen of HCC.
CONCLUSION: we have generated scFv dimers by shortening a series of linkers to 3-5 amino acid residues in VH-linker-VL orientation, resulting in highly stable and affinity-improved dimeric molecules. These will become an attractive targeting moiety in immunotherapeutic and diagnostic applications for HCC.

Entities:  

Keywords:  Affinity; Antibody-targeted; Diabody; Specificity; Stability

Year:  2010        PMID: 21160994      PMCID: PMC2998965          DOI: 10.4254/wjh.v2.i5.185

Source DB:  PubMed          Journal:  World J Hepatol


  22 in total

1.  scFv multimers of the anti-neuraminidase antibody NC10: length of the linker between VH and VL domains dictates precisely the transition between diabodies and triabodies.

Authors:  J L Atwell; K A Breheney; L J Lawrence; A J McCoy; A A Kortt; P J Hudson
Journal:  Protein Eng       Date:  1999-07

Review 2.  Improving the efficacy of antibody-based cancer therapies.

Authors:  P Carter
Journal:  Nat Rev Cancer       Date:  2001-11       Impact factor: 60.716

3.  Construction of a diabody (small recombinant bispecific antibody) using a refolding system.

Authors:  S Takemura; R Asano; K Tsumoto; S Ebara; N Sakurai; Y Katayose; H Kodama; H Yoshida; M Suzuki; K Imai; S Matsuno; T Kudo; I Kumagai
Journal:  Protein Eng       Date:  2000-08

4.  ScFv multimers of the anti-neuraminidase antibody NC10: shortening of the linker in single-chain Fv fragment assembled in V(L) to V(H) orientation drives the formation of dimers, trimers, tetramers and higher molecular mass multimers.

Authors:  O Dolezal; L A Pearce; L J Lawrence; A J McCoy; P J Hudson; A A Kortt
Journal:  Protein Eng       Date:  2000-08

5.  Immunosuppressive properties of anti-CD3 single-chain Fv and diabody.

Authors:  Fabrice Le Gall; Uwe Reusch; Gerhard Moldenhauer; Melvyn Little; Sergey M Kipriyanov
Journal:  J Immunol Methods       Date:  2004-02-01       Impact factor: 2.303

6.  Antigen binding and stability properties of non-covalently linked anti-CD22 single-chain Fv dimers.

Authors:  Michaela A E Arndt; Jürgen Krauss; Susanna M Rybak
Journal:  FEBS Lett       Date:  2004-12-17       Impact factor: 4.124

7.  Tumor localization of anti-CEA single-chain Fvs: improved targeting by non-covalent dimers.

Authors:  A M Wu; W Chen; A Raubitschek; L E Williams; M Neumaier; R Fischer; S Z Hu; T Odom-Maryon; J Y Wong; J E Shively
Journal:  Immunotechnology       Date:  1996-02

Review 8.  New protein engineering approaches to multivalent and bispecific antibody fragments.

Authors:  A Plückthun; P Pack
Journal:  Immunotechnology       Date:  1997-06

9.  Crystal structure of a diabody, a bivalent antibody fragment.

Authors:  O Perisic; P A Webb; P Holliger; G Winter; R L Williams
Journal:  Structure       Date:  1994-12-15       Impact factor: 5.006

10.  The 2.0-A resolution crystal structure of a trimeric antibody fragment with noncognate VH-VL domain pairs shows a rearrangement of VH CDR3.

Authors:  X Y Pei; P Holliger; A G Murzin; R L Williams
Journal:  Proc Natl Acad Sci U S A       Date:  1997-09-02       Impact factor: 11.205

View more
  1 in total

1.  Production and evaluation of a recombinant chimeric vaccine against clostridium botulinum neurotoxin types C and D.

Authors:  Luciana A F Gil; Carlos Eduardo P da Cunha; Gustavo M S G Moreira; Felipe M Salvarani; Ronnie A Assis; Francisco Carlos F Lobato; Marcelo Mendonça; Odir A Dellagostin; Fabricio R Conceição
Journal:  PLoS One       Date:  2013-07-31       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.